A Phase 3 interventional study of Doxorubicin and Docetaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 54 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-03.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 65th largest by enrollment of the 366 interventional ones that give a count, is one of 26 that started in 2013, is one of 60 in phase 3, and was the 206th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 26 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 61st largest by enrollment of the 170 interventional ones that give a count, is one of 11 that started in 2013, is one of 61 in phase 3, and was the 116th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This non-randomized, multicenter, open-label study will assess the safety and efficacy of subcutaneously administered trastuzumab in participants with early and locally advanced HER2-positive breast cancer in two sequential cohorts. First 120 participants will be treated with subcutaneous (SC) trastuzumab 600 milligrams (mg) vial (Cohort A) and the subsequent 120 participants will be treated with SC trastuzumab prefilled single use injection device (SID) (Cohort B). Participants from each cohort will receive neoadjuvant or adjuvant chemotherapy consisting of doxorubicin every 3 weeks (q3w) (1 cycle) for 4 cycles followed by paclitaxel weekly or docetaxel every 3 weeks (q3w) in combination with SC trastuzumab (600 mg) q3w for 4 cycles and a further 14 cycles of SC trastuzumab (600 mg) q3w alone. All participants will be followed up for 24 months after the last participant has received the last dose of study treatment, or earlier in case of withdrawal from the study, loss to follow-up or death.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive trastuzumab 600 mg SC using a vial q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy \[consisting of doxorubicin, paclitaxel or docetaxel\] and 14 cycles administered alone).
Drug: Doxorubicin · Drug: Docetaxel · Drug: Paclitaxel · Drug: Trastuzumab
Participants will receive trastuzumab 600 mg SC using SID q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy \[consisting of doxorubicin, paclitaxel or docetaxel\] and 14 cycles administered alone).
Drug: Doxorubicin · Drug: Docetaxel · Drug: Paclitaxel · Drug: Trastuzumab
Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.
Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.
Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
Also known as: Herceptin
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were the AEs occurring from starting on the day of or after first administration of trastuzumab and within 28 days after last dose of trastuzumab. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
Time frame: Day 1 up to 28 days after last dose of trastuzumab (up to approximately 1 year)
Actual Dose of Trastuzumab Administered
Actual dose (mg) administered = (sum over all cycles of actual dose received \[mg\] divided by number of cycles). Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
Time frame: Day 1 up last dose of trastuzumab (up to approximately 1 year)
Duration of Treatment With Trastuzumab
Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
Time frame: Day 1 up last dose of trastuzumab (up to approximately 1 year)
Percentage of Participants Who Received Concomitant Medications
Time frame: Screening (Day -28 to -1) up to 2.5 years
Percentage of Participants With Pathological Complete Response (pCR) (Neoadjuvant Groups Only) Using Mammography
In the neoadjuvant setting, the activity of two sequential drug regimens, doxorubicin-containing chemotherapy followed by paclitaxel or docetaxel chemotherapy in combination with trastuzumab, was assessed as the percentage of participants with pCR in breast and nodes using mammography. pCR was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after preoperative treatment. Data for this outcome measure were analyzed and reported only for neoadjuvant groups within each treatment arm.
Time frame: Day 1 up to 24 weeks
Percentage of Participants With Event (Local, Regional or Distant Recurrence, Contralateral Breast Cancer or Death) Using Mammography
A participant was considered as disease free if the participant was free from local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Percentage of participants with event at the cut off date were reported. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
Time frame: Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])
Disease-Free Survival (DFS) Using Mammography
DFS was defined as the time from the first treatment to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Kaplan-Meier estimates were used for analysis. Participants who were disease-free were censored at the data cut off date. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
Time frame: Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])
Percentage of Participants Who Died
Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
Time frame: Day 1 up to death due to any cause (up to approximately 4.5 years)
Overall Survival (OS)
Overall survival was defined as the time from the first treatment to death from any cause. Kaplan-Meier estimates were used for analysis. Participants who did not die were censored on the date they were last known to be alive. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
Time frame: Day 1 up to death due to any cause (up to approximately 4.5 years)
Percentage of Participants by Response to Patient Satisfaction Questionnaire (PSQ)
Participants were asked the following 5 questions: (1) "Following the first injection given by the physician/nurse and training on how to use the SID, I felt comfortable injecting the study drug by myself"; (2) "The SID was convenient and easy to use"; (3) "I am confident giving myself an injection in the thigh with the SID"; (4) "Taking all things into account, I find self-administration using the SID satisfactory"; (5) "If given the opportunity, I would choose to continue self-injecting the study drug using the SID at home". Response to each question was recorded as either of the following options: "Unknown", "Strongly Disagree", "Disagree", "Unsure", "Agree", "Strongly Agree". Percentage of participants who provided responses to above questions was reported. Data for this outcome measure were analyzed and reported only for Trastuzumab (SID) arm.
Time frame: After at least 14 cycles (1 cycle = 21 days; maximum up to 1 year)
Percentage of Health Care Professionals (HCPs) by Response to Health Care Professional Questionnaire (HCPQ)
Percentage of HCPs providing responses to various questions related to overall ease of study drug administration was reported in different categories, where categories indicate all possible responses to such questions.
Time frame: After at least 4 participants completed 5 cycles of adjuvant treatment (1 cycle = 21 days; maximum up to 1 year)
| Milestone | Trastuzumab (Vial) | Trastuzumab (SID) |
|---|---|---|
| Started | 121 | 119 |
| Treated | 115 | 113 |
| Treated: adjuvant | 95 | 92 |
| Treated: neoadjuvant | 20 | 21 |
| Completed | 100 | 101 |
| Not completed | 21 | 18 |
| Withdrew: Adverse event/intercurrent illness | 11 | 8 |
| Withdrew: Recurrence of disease postsurgery | 1 | 3 |
| Withdrew: Violation of entry criteria | 1 | 1 |
| Withdrew: Refused treatment | 1 | 3 |
| Withdrew: Withdrew consent | 6 | 2 |
| Withdrew: Administrative/other | 1 | 1 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were the AEs occurring from starting on the day of or after first administration of trastuzumab and within 28 days after last dose of trastuzumab. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
| Percentage of Participants | Trastuzumab (Vial): Adjuvant | Trastuzumab (Vial): Neoadjuvant | Trastuzumab (SID): Adjuvant | Trastuzumab (SID): Neoadjuvant |
|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | 98.9 | 100.0 | 89.1 | 95.2 |
Actual dose (mg) administered = (sum over all cycles of actual dose received \[mg\] divided by number of cycles). Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
| mg | Trastuzumab (Vial): Adjuvant | Trastuzumab (Vial): Neoadjuvant | Trastuzumab (SID): Adjuvant | Trastuzumab (SID): Neoadjuvant |
|---|---|---|---|---|
| Actual Dose of Trastuzumab Administered | 599.7 ± 3.08 | 600.00 ± 0.000 | 593.3 ± 16.55 | 595.9 ± 10.4 |
Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
| days | Trastuzumab (Vial): Adjuvant | Trastuzumab (Vial): Neoadjuvant | Trastuzumab (SID): Adjuvant | Trastuzumab (SID): Neoadjuvant |
|---|---|---|---|---|
| Duration of Treatment With Trastuzumab | 346 ± 72.13 | 352.2 ± 55.82 | 340.1 ± 85.47 | 351.9 ± 90.02 |
| Percentage of Participants | Trastuzumab (Vial) | Trastuzumab (SID) |
|---|---|---|
| Percentage of Participants Who Received Concomitant Medications | 100 | 100 |
In the neoadjuvant setting, the activity of two sequential drug regimens, doxorubicin-containing chemotherapy followed by paclitaxel or docetaxel chemotherapy in combination with trastuzumab, was assessed as the percentage of participants with pCR in breast and nodes using mammography. pCR was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after preoperative treatment. Data for this outcome measure were analyzed and reported only for neoadjuvant groups within each treatment arm.
| Percentage of Participants | Trastuzumab (Vial): Neoadjuvant | Trastuzumab (SID): Neoadjuvant |
|---|---|---|
| Percentage of Participants With Pathological Complete Response (pCR) (Neoadjuvant Groups Only) Using Mammography | 40.9 (31.0 to 51.0) | 15.8 (8.00 to 24.0) |
A participant was considered as disease free if the participant was free from local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Percentage of participants with event at the cut off date were reported. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
| Percentage of Participants | Trastuzumab (Vial): Adjuvant | Trastuzumab (Vial): Neoadjuvant | Trastuzumab (SID): Adjuvant | Trastuzumab (SID): Neoadjuvant |
|---|---|---|---|---|
| Percentage of Participants With Event (Local, Regional or Distant Recurrence, Contralateral Breast Cancer or Death) Using Mammography | 18.5 | 33.3 | 6.6 | 11.1 |
DFS was defined as the time from the first treatment to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Kaplan-Meier estimates were used for analysis. Participants who were disease-free were censored at the data cut off date. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
| Months | Trastuzumab (Vial): Adjuvant | Trastuzumab (Vial): Neoadjuvant | Trastuzumab (SID): Adjuvant | Trastuzumab (SID): Neoadjuvant |
|---|---|---|---|---|
| Disease-Free Survival (DFS) Using Mammography | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
| Percentage of Participants | Trastuzumab (Vial): Adjuvant | Trastuzumab (Vial): Neoadjuvant | Trastuzumab (SID): Adjuvant | Trastuzumab (SID): Neoadjuvant |
|---|---|---|---|---|
| Percentage of Participants Who Died | 5.2 | 4.5 | 0.0 | 5.26 |
Overall survival was defined as the time from the first treatment to death from any cause. Kaplan-Meier estimates were used for analysis. Participants who did not die were censored on the date they were last known to be alive. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
| Months | Trastuzumab (Vial): Adjuvant | Trastuzumab (Vial): Neoadjuvant | Trastuzumab (SID): Adjuvant | Trastuzumab (SID): Neoadjuvant |
|---|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Participants were asked the following 5 questions: (1) "Following the first injection given by the physician/nurse and training on how to use the SID, I felt comfortable injecting the study drug by myself"; (2) "The SID was convenient and easy to use"; (3) "I am confident giving myself an injection in the thigh with the SID"; (4) "Taking all things into account, I find self-administration using the SID satisfactory"; (5) "If given the opportunity, I would choose to continue self-injecting the study drug using the SID at home". Response to each question was recorded as either of the following options: "Unknown", "Strongly Disagree", "Disagree", "Unsure", "Agree", "Strongly Agree". Percentage of participants who provided responses to above questions was reported. Data for this outcome measure were analyzed and reported only for Trastuzumab (SID) arm.
| Percentage of Participants | Trastuzumab (SID) |
|---|---|
| Comfortable: Unknown | 0.0 |
| Comfortable: Strongly Disagree | 0.0 |
| Comfortable: Disagree | 0.0 |
| Comfortable: Unsure | 6.7 |
| Comfortable: Agree | 40 |
| Comfortable: Strongly Agree | 53.3 |
| Convenient: Unknown | 0.0 |
| Convenient: Strongly Disagree | 0.0 |
| Convenient: Disagree | 0.0 |
| Convenient: Unsure | 6.7 |
| Convenient: Agree | 33.3 |
| Convenient: Strongly Agree | 60 |
| Confident: Unknown | 0.0 |
| Confident: Strongly Disagree | 0.0 |
| Confident: Disagree | 0.0 |
| Confident: Unsure | 6.7 |
| Confident: Agree | 40.0 |
| Confident: Strongly Agree | 53.3 |
| Satisfactory: Unknown | 0.0 |
| Satisfactory: Strongly Disagree | 0.0 |
| Satisfactory: Disagree | 0.0 |
| Satisfactory: Unsure | 6.7 |
| Satisfactory: Agree | 33.3 |
| Satisfactory: Strongly Agree | 60 |
| Would continue: Unknown | 0.0 |
| Would continue: Strongly Disagree | 0.0 |
| Would continue: Disagree | 13.3 |
| Would continue: Unsure | 6.7 |
| Would continue: Agree | 20 |
| Would continue: Strongly Agree | 60 |
Percentage of HCPs providing responses to various questions related to overall ease of study drug administration was reported in different categories, where categories indicate all possible responses to such questions.
| Percentage of HCPs | HCPs: Trastuzumab (Vial) | HCPs: Trastuzumab (SID) |
|---|---|---|
| Specialization: Oncologist | 17.3 | 16.0 |
| Specialization: Specialist nurse | 69.2 | 76.0 |
| Specialization: Other | 11.5 | 8.0 |
| Specialization: Missing | 1.9 | 0.0 |
| Personally administered/supervised: Always | 40.4 | 48.0 |
| Personally administered/supervised: Sometimes | 51.9 | 48.0 |
| Personally administered/supervised: Never | 7.7 | 4.0 |
| If 'Never', who administered: Specialist nurse | 7.7 | 4.0 |
| Syringe prepared at: Pharmacy | 55.8 | NA |
| Syringe prepared at: Oncology ward | 40.4 | NA |
| Syringe prepared at: Missing | 3.8 | NA |
| Time to fill syringe: less than (<) 5 minutes | 67.3 | NA |
| Time to fill syringe: 6-10 minutes | 13.5 | NA |
| Time to fill syringe: 11-15 minutes | 5.8 | NA |
| Time to fill syringe: Unknown | 13.5 | NA |
| Total time for vial administration: <3 minutes | 1.9 | NA |
| Total time for vial administration: <5 minutes | 59.6 | NA |
| Total time for vial administration: 6-15 minutes | 38.5 | NA |
| Time to prepare SID: <5 minutes | NA | 72.0 |
| Time to prepare SID: 6-10 minutes | NA | 14.0 |
| Time to prepare SID: 11-15 minutes | NA | 4.0 |
| Time to prepare SID: 16-20 minutes | NA | 2.0 |
| Time to prepare SID: >20 minutes | NA | 8.0 |
| Total time for SID administration: <3 minutes | NA | 26.0 |
| Total time for SID administration: <5 minutes | NA | 30.0 |
| Total time for SID administration: 6-15 minutes | NA | 44.0 |
| Injection site: Irritation: A lot | 1.9 | 4.0 |
| Injection site: Irritation: A few | 46.2 | 36.0 |
| Injection site: Irritation: None | 51.9 | 60.0 |
| Injection site: Bruising: A few | 7.7 | 10.0 |
| Injection site: Bruising: None | 92.3 | 90.0 |
| Injection site: Infection: None | 100.0 | 100.0 |
| Fever,shivering,flu-like,rash,swelling:A few | 15.4 | 14.0 |
| Fever,shivering,flu-like,rash,swelling:None | 84.6 | 86.0 |
| Time at hospital for administration: <2 hours | 44.2 | 44.0 |
| Time at hospital for administration: >2, <3 hours | 23.1 | 34.0 |
| Time at hospital for administration: >3, <4 hours | 23.1 | 12.0 |
| Time at hospital for administration: >4 hours | 7.7 | 10.0 |
| Time at hospital for administration: Missing | 1.9 | 0.0 |
| Anxiety to participants: None | 82.7 | 90.0 |
| Anxiety to participants: A fair amount | 17.3 | 10.0 |
| Ease of vial administration: None | 5.8 | NA |
| Ease of vial administration: A fair amount | 38.5 | NA |
| Ease of vial administration: A lot | 55.8 | NA |
| Subcutaneous route may simplify management: Yes | 94.2 | 100.0 |
| Subcutaneous route may simplify management: No | 5.8 | 0.0 |
| Would recommend SID to intravenous route: Yes | 96.2 | 96.0 |
| Would recommend SID to intravenous route: No | 3.8 | 4.0 |
| Would recommend subcutaneous route to medics: Yes | 100.0 | 90.0 |
| Would recommend subcutaneous route to medics: No | 0.0 | 8.0 |
| Would recommend subcutaneous to medics:Missing | 0.0 | 2.0 |
| Convenience of using SID by participants: Yes | 94.2 | 96.0 |
| Convenience of using SID by participants: No | 0.0 | 4.0 |
| Convenience of using SID by participants: Missing | 5.8 | 0.0 |
Collected over Day 1 up to 28 days after last dose of trastuzumab. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab (Vial): Adjuvant | 5/95 (5.3%) | 5/95 (5.3%) | 92/95 (96.8%) |
| Trastuzumab (Vial): Neoadjuvant | 1/20 (5%) | 3/20 (15%) | 20/20 (100%) |
| Trastuzumab (SID) Adjuvant | 0/92 (0%) | 7/92 (7.6%) | 79/92 (85.9%) |
| Trastuzumab (SID) Neoadjuvant | 1/21 (4.8%) | 2/21 (9.5%) | 18/21 (85.7%) |
| Event | Trastuzumab (Vial): Adjuvant | Trastuzumab (Vial): Neoadjuvant | Trastuzumab (SID) Adjuvant | Trastuzumab (SID) Neoadjuvant |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/95 | 1/20 | 0/92 | 0/21 |
| PleuropericarditisCardiac disorders | 0/95 | 1/20 | 0/92 | 0/21 |
| GastroenteritisInfections and infestations | 0/95 | 1/20 | 0/92 | 0/21 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/95 | 1/20 | 0/92 | 0/21 |
| VomitingGastrointestinal disorders | 0/95 | 0/20 | 0/92 | 1/21 |
| NeutropeniaBlood and lymphatic system disorders | 0/95 | 0/20 | 0/92 | 1/21 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/95 | 0/20 | 1/92 | 0/21 |
| PryexiaGeneral disorders | 0/95 | 0/20 | 1/92 | 0/21 |
| Anaphylactic shockImmune system disorders | 1/95 | 0/20 | 1/92 | 0/21 |
| Bladder transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/95 | 0/20 | 1/92 | 0/21 |
| Event | Trastuzumab (Vial): Adjuvant | Trastuzumab (Vial): Neoadjuvant | Trastuzumab (SID) Adjuvant | Trastuzumab (SID) Neoadjuvant |
|---|---|---|---|---|
| ParaesthesiaNervous system disorders | 49/95 | 3/20 | 25/92 | 3/21 |
| AstheniaGeneral disorders | 32/95 | 3/20 | 20/92 | 7/21 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 29/95 | 4/20 | 28/92 | 5/21 |
| DiarrhoeaGastrointestinal disorders | 25/95 | 3/20 | 15/92 | 6/21 |
| Hot flushVascular disorders | 7/95 | 5/20 | 7/92 | 2/21 |
| HypertensionVascular disorders | 7/95 | 5/20 | 8/92 | 1/21 |
| ErythemaSkin and subcutaneous tissue disorders | 23/95 | 2/20 | 14/92 | 2/21 |
| NeutropeniaBlood and lymphatic system disorders | 20/95 | 4/20 | 4/92 | 0/21 |
| PyrexiaGeneral disorders | 18/95 | 4/20 | 13/92 | 4/21 |
| AnaemiaBlood and lymphatic system disorders | 15/95 | 2/20 | 7/92 | 4/21 |
Intent-to-treat (ITT) population included all enrolled participants.
| Age, Continuous(years) | Trastuzumab (Vial) | Trastuzumab (SID) | Total |
|---|---|---|---|
| Mean | 55.1 ± 10.51 | 53.2 ± 10.37 | 54.2 ± 10.46 |
| Sex: Female, Male(Participants) | Trastuzumab (Vial) | Trastuzumab (SID) | Total |
|---|---|---|---|
| Female | 120 | 119 | 239 |
| Male | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2013 to primary completion in Apr 2016, 28 months.
Results were first posted in Jul 2017, 1 year 2 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 28 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab